Skip to Content
Merck
CN

Key Documents

View All Documentation

SML3914

Cabozantinib

≥98% (HPLC)

Synonym(s):

N-(4-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane1,1-dicarboxamide, BMS 907351, BMS-907351, BMS907351, N-(4-{[6,7-bis(Methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, XL 184, XL-184, XL184

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C28H24FN3O5
CAS Number:
849217-68-1
Molecular Weight:
501.51
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD20926324
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

Fc1ccc(cc1)NC(=O)C5(CC5)C(=O)Nc2ccc(cc2)Oc3c4c(ncc3)cc(c(c4)OC)OC

InChI

1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)

InChI key

ONIQOQHATWINJY-UHFFFAOYSA-N

Biochem/physiol Actions

Cabozantinib (XL184; BMS‐907351) is an orally active, potent inhibitor against multiple receptor tyrosine kinases, notably VEGFR2/KDR (IC50 = 35 pM), MET (IC50 = 1.3 nM/wt, 3.8 nM/Y1248H, 11.8 nM/D1246N, 14.6 nM/K1262R), KIT, RET, AXL, TIE2, and FLT3 (IC50 = 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib inhibits MET-driven proliferation in cancer cultures (IC50 = 9.9 nM/Hs746T, 19 nM/SNU-5) and simultaneously suppressing metastasis, angiogenesis and tumor growth in vivo (3-100 mg/kg via single or daily p.o. to mice with human MDA-MB-231 xenograft, 1-60 mg/kg via single or daily p.o. to rats with C6 rat glioma).
Orally active, potent receptor tyrosine kinase inhibitor against VEGFR2 (KDR), MET, KIT, RET, AXL, TIE2, and FLT3 with anti-tumor efficacy in vivo.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B - STOT RE 2

target_organs

Bone marrow,Kidney,Endocrine system,Gastrointestinal tract,Liver

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000514298
0000514301
0000514301
0000514298
0000425772

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor
Pharmacotherapy, 38(3), 357-369 (2018)
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Clinical Cancer Research, 28(11), 2449-2460 (2022)
F Michael Yakes et al.
Molecular cancer therapeutics, 10(12), 2298-2308 (2011-09-20)
The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a

Global Trade Item Number

SKUGTIN
SML3914-10MG04065270750396
SML3914-50MG04065270750402